Department of Health Policy Archive — Page 2 of 15
-
June 18, 2024
Study tallies reports of unprofessional behavior among physicians
Reports from 193 hospitals were analyzed. It turns out that surgeons draw the most complaints. -
June 11, 2024
2024 Chancellor Faculty Fellows selected
Each fellow holds the title for two years, receives $40,000 per year to support their work, and meets with their cohort to exchange ideas, build a broader intellectual community and engage in academic leadership development. -
May 16, 2024
Clinician accountability program from VUMC associated with large savings
A program run by Vanderbilt University Medical Center that provides peer feedback to high-risk clinicians was associated with a significant decrease in malpractice claims costs at a large orthopaedic surgery practice, according to a recent study. -
May 13, 2024
Training grant builds research ethics capacity for genetic and genomic research in Nigeria
The long-standing partnership between Vanderbilt Institute for Global Health (VIGH) and collaborators Aminu Kano Teaching Hospital (AKTH) and Bayero University (BUK) is poised to address the growing demand for research in precision medicine in Africa. -
May 6, 2024
Second-most used herbicide in the US linked to birth defect in national study
At present, 44 countries, including the European Union, have banned or are phasing out atrazine due to concern for its negative effects on human health. -
April 25, 2024
Traditional healer-initiated HIV testing and care expands in South Africa
Developed in a region with the world’s highest HIV prevalence, this study design and intervention has the potential to impact testing uptake among a “hidden population” by mobilizing trained healers, who vastly outnumber allopathic care providers in South Africa. -
April 17, 2024
Common AFib drug linked to higher bleeding risk
In a national retrospective study led by researchers at Vanderbilt University School of Medicine, diltiazem, when given in combination with the anticoagulant drugs apixaban (Eliquis) or rivaroxaban (Xarelto), significantly increased the risk of serious bleeding compared to metoprolol.